1489 related articles for article (PubMed ID: 17598963)
21. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
[TBL] [Abstract][Full Text] [Related]
22. Frequency and clinical evolution of indeterminate colitis: a retrospective multi-centre study in northern Italy. GSMII (Gruppo di Studio per le Malattie Infiammatorie Intestinali).
Meucci G; Bortoli A; Riccioli FA; Girelli CM; Radaelli F; Rivolta R; Tatarella M
Eur J Gastroenterol Hepatol; 1999 Aug; 11(8):909-13. PubMed ID: 10514127
[TBL] [Abstract][Full Text] [Related]
23. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
[TBL] [Abstract][Full Text] [Related]
24. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Wajda A; Blanchard JF
Gastroenterology; 2005 Sep; 129(3):827-36. PubMed ID: 16143122
[TBL] [Abstract][Full Text] [Related]
25. Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study.
Wolters FL; Russel MG; Sijbrandij J; Schouten LJ; Odes S; Riis L; Munkholm P; Langholz E; Bodini P; O'Morain C; Katsanos K; Tsianos E; Vermeire S; Van Zeijl G; Limonard C; Hoie O; Vatn M; Moum B; Stockbrügger RW;
Scand J Gastroenterol Suppl; 2006; (243):46-54. PubMed ID: 16782622
[TBL] [Abstract][Full Text] [Related]
26. Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
Gupta G; Gelfand JM; Lewis JD
Gastroenterology; 2005 Sep; 129(3):819-26. PubMed ID: 16143121
[TBL] [Abstract][Full Text] [Related]
27. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
[TBL] [Abstract][Full Text] [Related]
28. The cause of death in inflammatory bowel disease: a comparison of death certificates and hospital charts in Rochester, New York.
Nordenholtz KE; Stowe SP; Stormont JM; Stowe MM; Chessin LN; Shah AN; Chey WY
Am J Gastroenterol; 1995 Jun; 90(6):927-32. PubMed ID: 7771423
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic problems and advances in inflammatory bowel disease.
Odze R
Mod Pathol; 2003 Apr; 16(4):347-58. PubMed ID: 12692200
[TBL] [Abstract][Full Text] [Related]
30. Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey.
Haapamäki J; Turunen U; Roine RP; Färkkilä MA; Arkkila PE
Scand J Gastroenterol; 2008; 43(7):821-30. PubMed ID: 18584521
[TBL] [Abstract][Full Text] [Related]
31. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?
Rubin DT; Rothe JA; Hetzel JT; Cohen RD; Hanauer SB
Gastrointest Endosc; 2007 Jun; 65(7):998-1004. PubMed ID: 17451704
[TBL] [Abstract][Full Text] [Related]
32. [Familial prevalence in chronic intestinal inflammatory disease. Differences among groups of patients with and without a familial history].
Nos P; Argüello L; Hoyos M; Ramírez JJ; Hinojosa J; Molés JR; García A; Berenguer M; Berenguer J
Rev Esp Enferm Dig; 1996 Jul; 88(7):470-4. PubMed ID: 8924324
[TBL] [Abstract][Full Text] [Related]
33. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.
Korelitz BI; Mirsky FJ; Fleisher MR; Warman JI; Wisch N; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3248-53. PubMed ID: 10566724
[TBL] [Abstract][Full Text] [Related]
34. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye.
Beaugerie L; Sokol H; Seksik P
Dig Dis; 2009; 27(3):375-81. PubMed ID: 19786768
[TBL] [Abstract][Full Text] [Related]
35. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial.
Irvine EJ; Zhou Q; Thompson AK
Am J Gastroenterol; 1996 Aug; 91(8):1571-8. PubMed ID: 8759664
[TBL] [Abstract][Full Text] [Related]
36. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study.
Bernstein CN; Blanchard JF; Houston DS; Wajda A
Thromb Haemost; 2001 Mar; 85(3):430-4. PubMed ID: 11307809
[TBL] [Abstract][Full Text] [Related]
37. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
38. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.
Bernstein CN; Papineau N; Zajaczkowski J; Rawsthorne P; Okrusko G; Blanchard JF
Am J Gastroenterol; 2000 Mar; 95(3):677-83. PubMed ID: 10710056
[TBL] [Abstract][Full Text] [Related]
39. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Wajda A; Blanchard JF
Clin Gastroenterol Hepatol; 2008 Jan; 6(1):41-5. PubMed ID: 18063423
[TBL] [Abstract][Full Text] [Related]
40. Risk of arterial thrombotic events in inflammatory bowel disease.
Ha C; Magowan S; Accortt NA; Chen J; Stone CD
Am J Gastroenterol; 2009 Jun; 104(6):1445-51. PubMed ID: 19491858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
